News Archive
November 2008: PDS Biotechnology Corporation completes a second round of funding with Asklepios Capital, LLC and the Labrum Trust.
October 2008: The National Cancer Institute (NCI), a branch of the United States National Institutes of Health (NIH), awards PDS Biotechnology Corporation a grant to initiate toxicology studies of Versamune™ –HPV in rodents and monkeys geared towards an IND filing with the FDA and initiation of human clinical trials.
September 2008: Dr. Mark Einstein, M.S., M.D., Director of Clinical Research, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Women’s Health, Albert Einstein College of Medicine, Albert Einstein Cancer Center, and Montefiore Medical Center, an internationally renowned cervical cancer researcher and clinical expert in HPV-related disease joins PDS Biotechnology's scientific advisory board.
September, 2008: The National Cancer Institute (NCI), awards PDS Biotechnology a Small Business Innovation Research (SBIR) grant to develop Versamune™ –Melanoma, a therapy for melanoma, the most aggressive form of skin cancer, based on the company's simple nanoparticle Versamune™ platform technology.
June, 2008: The Nanotechnology Characterization Laboratory (NCL) selected PDS Biotechnology as an affiliate to collaborate on the development of PDS Biotechnology's HPV cancer immunotherapy Versamune™ –HPV. The NCL is a collaboration between the NCI, the FDA and NIST aimed at accelerating promising cancer nanotechnologies through regulatory submissions to clinical development.
September, 2007: The National Cancer Institute (NCI) awards PDS Biotechnology Corporation an SBIR contract to develop a therapy for cancers related to infection with the human papilloma virus. The award was based on successful review of the company’s proprietary cationic lipid nanoparticle technology Versamune™ and drug development strategy. These cancers include cervical, anal and head and neck cancers. There are currently no FDA approved therapies for these cancers.
September, 2007: PDS Biotechnology Corporation received a notice of approval of the company’s patent claims filed May, 2005, patent #7303881. The patent covers the use of the Versamune™ technology in the development of immunotherapies to treat cancer and infectious diseases.
August, 2007: Dr. Bedu-Addo, President and CEO of PDS Biotechnology, invited to present “Potent and Targeted Lipid-based Immunotherapy for the Treatment of Cancer and Viral Diseases.” at the World Vaccine Congress, Europe. October 8-10, 2007, Palais des Congrès de Lyon, Lyon, France.
April, 2007: Dr. Bedu-Addo, President and CEO of PDS Biotechnology, invited to present “A Cationic Lipid-Based Immunotherapy Technology for Use in the Development of Cancer and Antiviral Drugs” at the World Vaccine Congress, Asia. June 4-7, 2007, Meritus Mandarin, Singapore.
